My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Ipsen Sa S/Adr (OP:IPSEY)

44.93 +0.79 (+1.78%)

Streaming Delayed Price Updated: 10:13 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ipsen Sa S/Adr

< Previous 1 2 Next >

Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal ↗

July 13, 2024

In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson.

Via Talk Markets

Topics Initial Public Offering

FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo ↗

June 11, 2024

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability...

Via Benzinga

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

November 10, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases ↗

September 19, 2022

Via Benzinga

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

November 01, 2023

Virtual Investor Conference on November 8th and 9th, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Via Benzinga

Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗

June 30, 2023

Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:

Via Benzinga

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients ↗

June 30, 2023

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)

Via Benzinga

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗

May 22, 2023

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...

Via Benzinga

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 09, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

May 18, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

January 27, 2023

From Ipsen

Via Business Wire

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

January 20, 2023

From Ipsen

Via Business Wire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 15, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Why These Two Biotech Stocks Blasted Higher This Week ↗

January 13, 2023

There's nothing like a big-premium buyout to send a company's share price to the moon.

Via The Motley Fool

2 Tiny Nasdaq Stocks Making Major Merger Moves Monday ↗

January 09, 2023

The market is moving higher, and these small companies are helping.

Via The Motley Fool

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline ↗

January 09, 2023

Via Benzinga

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

January 09, 2023

From Ipsen

Via Business Wire

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

December 23, 2022

From Ipsen

Via Business Wire

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

December 08, 2022

From Ipsen

Via Business Wire

Why Merrimack Shares Are Surging Over 200% Today? ↗

November 09, 2022

Via Benzinga

Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

November 09, 2022

From Ipsen

Via Business Wire

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance

October 27, 2022

From Ipsen

Via Business Wire

Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting

October 25, 2022

From Ipsen

Via Business Wire

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

August 12, 2022

From Ipsen

Via Business Wire

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

August 05, 2022

From Ipsen

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition